[1] 国家卫生计生委合理用药专家委员会,中国医师协会高血压专业委员会.高血压合理用药指南(第2版)[J].中国医学前沿杂志:电子版,2017,7:28-126. [2] 张正冬,张海燕,林存智.WHO第四版结核病治疗指南解读[J].中华临床医师杂志,2014,8(23):4251-4253. [3] 中华医学会结核病学分会,抗结核药物超说明书用法专家共识编写组.抗结核药物超说明书用法专家共识[J].中华结核和呼吸杂志,2018,6:447-460. [4] 李国境,才江平,魏宁.利福平致血压升高12例临床分析[J].宁夏医科大学学报,2018,40(4):460-461. [5] 张慧清,李博卷.利福平引起高血压病患者血压改变46例临床观察[J].实用医技杂志,2018,25(10):1157-1158. [6] 中华人民共和国卫生部.布鲁氏菌病诊疗指南(试行)[J].传染病信息,2012,25(6):323-324,359. [7] GORSKI J C,VANNAPRASAHT S,HAMMAN M A,et al.The effect of age,sex,and rifampin administration on intestinal and hepatic cytochrome P4503A activity[J].Clin Pharmacol Ther,2003,74(3):275-287. [8] XU Y,ZHOU Y,HAYASHI M,et al.Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs[J].Drug Metab Dispos,2011,39(7):1139-1148. [9] WILLIAMSON K M,PATTERSON J H,MCQUEEN R H,et al.Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers[J].Clin Pharmacol Ther,1998,63(3):316-323. [10] 刘超,应颖秋.1例利福平与氨氯地平相互作用的病例分析[J].临床药物治疗杂志,2017,15(3):75-77. [11] CORDEANU E M,GAERTNER S,FALLER A,et al.Rifampicin reverses nicardipine effect inducing uncontrolled essential hypertension[J].Fundam Clin Pharmacol,2017,31(5):587-589. [12] 王成章,蔡长春.赖诺普利与利福平合用致持续高血压一例[J].中华老年医学杂志,1999,18(3):169. [13] 甘道京,彭强,苏海.如何为合并结核病的高血压患者合理选择降压药物[J].中华高血压杂志,2014,22(4):301-303. [14] KIM H I,KIM T H,Kim H,et al.Effect of rifampin on thyroid function test in patients on levothyroxine medication[J].PLoS ONE,2017,12(1):e0169775. [15] ZHI J G,ZHAI S P,GEORGY A,et al.Exploratory effects of a strong CYP3A inhibitor (ketoconazole),a strong CYP3A inducer (rifampicin),and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients[J].J Clin Pharmacol,2016,56(5):548-554. [16] MENDELL J,CHEN S Q,HE L,et al.The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults[J].Clin Drug Investig,2015,35(7):447-453. [17] YAMAZAKI S,JOHNSON T R,SMITH B J.Prediction of drug-drug interactions with crizotinib as the CYP3A substrate using a physiologically based pharmacokinetic model[J].Drug Metab Dispos,2015,43(10):1417-1429. [18] BEUMER J H,PILLAI V C,PARISE R A,et al.Human hepatocyte assessment of imatinib drug-drug interactions-complexities in clinical translation[J].Br J Clin Pharmacol,2015,80(5):1097-1108. [19] LILJA J J,JUNTTI-PATINEN L,NEUVONEN P J.Effect of rifampicin on the pharmacokinetics of atenolol[J].Basic Clin Pharmacol Toxicol,2006,98(6):555-558. [20] 陈鲁原.高血压药物治疗原则及优化[J].中国实用内科杂志,2019,39(1):19-22. [21] 赵连友.重视个体化联合用药治疗高血压的临床价值[J].中国实用内科杂志,2019,39(1):1-4. [22] 孙平,吴广胜,梁迅.RITP患者血浆中利福平依赖性抗血小板抗体的特性及其作用机制[J].解放军医学杂志,2017,42(5):413-419. [23] CHOI J S,CHOI I,CHOI D H.Effects of nifedipine on the pharmacokinetics of repaglinide in rats:possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine[J].Pharmacol Rep,2013,65(5):1422-1430. |